| Title |
Diffuse large B cell lymphoma: molecular targeted therapy
|
|---|---|
| Published in |
International Journal of Hematology, October 2012
|
| DOI | 10.1007/s12185-012-1198-3 |
| Pubmed ID | |
| Authors |
Mark Roschewski, Kieron Dunleavy, Wyndham H. Wilson |
| Abstract |
Diffuse large B cell lymphoma (DLBCL) is a biologically heterogeneous disease and the most common subtype of B cell non-Hodgkin's lymphoma in the USA. Even though it is a curable lymphoma in advanced stages, up to 40 % of patients eventually relapse or fail to achieve remission. Improved understanding of the biologic complexity of DLBCL reveals a diverse range of oncogenic driver mutations and signaling pathways that are essential for growth and survival of malignant cells. Since many of these signaling pathways can be targeted by small-molecule inhibitors, the therapy for DLBCL is currently undergoing a paradigm shift away from conventional chemotherapy and toward targeted agents that capitalize on an improved biologic understanding of the subsets with the highest risk of treatment failure. Participation in well-conducted and rationally designed clinical trials will be essential to realize the potential of these targeted agents and realize the goal of improving overall outcomes in the most common B cell lymphoma in the world. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 33% |
| Science communicators (journalists, bloggers, editors) | 1 | 33% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Denmark | 1 | 2% |
| Unknown | 48 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 32% |
| Student > Ph. D. Student | 7 | 14% |
| Other | 6 | 12% |
| Student > Master | 5 | 10% |
| Student > Bachelor | 4 | 8% |
| Other | 5 | 10% |
| Unknown | 7 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 19 | 38% |
| Medicine and Dentistry | 12 | 24% |
| Biochemistry, Genetics and Molecular Biology | 4 | 8% |
| Veterinary Science and Veterinary Medicine | 2 | 4% |
| Chemistry | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 8 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 February 2014.
All research outputs
#14,194,875
of 22,753,345 outputs
Outputs from International Journal of Hematology
#611
of 1,388 outputs
Outputs of similar age
#101,100
of 176,112 outputs
Outputs of similar age from International Journal of Hematology
#9
of 17 outputs
Altmetric has tracked 22,753,345 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,388 research outputs from this source. They receive a mean Attention Score of 3.6. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,112 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.